Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri LR-99
- Development stage
- Unknown
- Lead developer
- Beijing Huayuan Academy of Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri LR-99 is a specific probiotic bacterial strain belonging to the *Lactobacillus* genus. It is primarily investigated for its role in the gut-brain axis, particularly for the treatment of core symptoms in children with autism spectrum disorder (ASD). The strain is hypothesized to exert its effects by modulating the gut microbiota, reducing systemic inflammation, and influencing the central nervous system through the vagus nerve and the stimulation of oxytocin production. In clinical settings, it is often evaluated as an adjunct to behavioral interventions like sensory integration therapy to improve social communication and behavioral outcomes.
- Other names
- L. reuteri LR-99Lactobacillus reuteri strain LR-99
02
Targets
Oxytocin receptor
Beyond the preview
Go deeper on Lactobacillus reuteri LR-99.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri LR-99.